

INDEX

Note: Page numbers in *italics* indicate figures.
Page numbers followed by a “t” indicate tables.
Gastroesophageal reflux disease is abbreviated as GERD.

- Abdominal pain, as side effect of PPIs, 149, 150
Abdominal pressure. See *Intra-abdominal pressure*.
Acetylcholine, 121, 123t, 125
 receptors, 121, 125
 site of action on parietal cell, 136
Acetylsalicylic acid (aspirin)
 esophagitis associated with use of, 118
 stricture induced by, 82t-83t
Acid, gastric. See *Gastric acid*.
Acid clearance, 25-29. See also *Esophageal clearance*.
 nocturnal reflux and, 25
 peristalsis and, 21
 salivary bicarbonate neutralization, 25
 swallowing and, 21
Acid-peptic disorder, 7
Acid perfusion (Bernstein) test, 71
 cautions for, 71
 sensitivity and specificity of, 64
Acid pump, 121, 135-136, 136
 inhibitors. See *Proton pump inhibitors*.
Acid reflux. See also *Gastroesophageal reflux*; *Nocturnal reflux*
 acid/alkaline reflux, 29-31
 standard test of, 64
 TLESRs and, 23
Acid-suppression therapy. See also *Pharmacologic management of GERD*.
 increased effectiveness with *Helicobacter pylori* infection, 97-98, 99-100, 100
 long-term
 Helicobacter pylori infection and atrophic gastritis risk, 97-99, 103-104
 safety of, 151-156
Aciphex. See *Rabeprazole*.
ADCE. See *Adenocarcinoma of the esophagus*.
Adenocarcinoma of the esophagus (ADCE)
 from Barrett's metaplasia, 80-81, 85, 86, 90-91
 Helicobacter pylori infection and, 93
 dysplasia and, 86-88, 88t, 91-92
 histologic sequence in development of, 86
 incidence of, 79, 85, 89
 gender and race in, 81
 risk factors, 89-90
 sleep disturbances and, 147
 surveillance/monitoring, 90-92, 91t
Aerophagia, 29
African Americans, Barrett's metaplasia and, 81
Age
 diagnostic workup and, 60
 paraesophageal hernia and, 34
 salivation and, 27
Airway reactivity, to esophageal acid. See *Asthma, GERD and*.

Alcohol, 117. See also *Ethanol*.
 esophageal sensitivity to, 44
 lower esophageal sphincter pressure and, 24
 reflux and, 112t, 115, 117
Alginic acid, 122t, 131
Allergies, inflammation and, 53
Aluminum
 in antacids, 130
 sucralfate, complex with, 134
Ambulatory manometric studies, 45
Ambulatory motility studies, 27
Ambulatory pH monitoring, 51, 53, 59, 60, 61-65
 wireless device for, 63-65
Amino acids, intestinal, 123t, 124
Aminolevulinic acid-based photodynamic therapy, 92
Ampicillin esters, PPI effect on bioavailability of, 150
Anemia
 adenocarcinoma and, 85
 as complication of erosive esophagitis, 77
 as diagnostic factor, 60, 85
 endoscopy examination in, 69
 proton pump inhibitors and, 155
Angina, induced by acid perfusion (Bernstein) test, 71
Antacids, 122t, 130
 action mechanisms, 124, 130
 adverse effects, 130
 drug interactions, 122t, 152t
 duration, 124, 130
 effects of, 122t
 fracture risk associated with, 156
 indications for, 130
 LESP increase due to, 23
 site of action, 136
 vs other agents, 122t
 yearly dollars spent on, 7
 for young patients, 60
Anticholinergics
 lower esophageal sphincter pressure and, 24
 salivation and, 27
 site of action, 136
Antipyrine (phenazone), 152t
Antireflux agents. See *Pharmacologic management of GERD*.
Antireflux surgery. See *Surgical management of GERD*.
Antral glands, 121, 124
Ascorbic acid, stricture induced by, 82t
Aspiration of acid, 23, 49, 51
 idiopathic pulmonary fibrosis from, 53
 pH monitoring and, 63
Aspiration pneumonia, 47t
Aspirin (acetylsalicylic acid), 82t-83t, 118
Asthma, 49-50
 Barrett's metaplasia and, 84
 GERD and, 7, 44, 47t, 49-50
 bronchodilators and, 49
 frequency of association, 49
 mechanisms of association, 49-50

Asthma (*continued*)
 nocturnal acid breakthrough in, 147
 prevalence in ProGERD study, 49
Atrophic gastritis, *Helicobacter pylori* infection and, 97-99, 102, 103-104
Atropine, to reverse bronchospasm, 50
Axid (nizatidine), 126t, 132, 143

Bacterial overgrowth
 gastric acid inhibition and, 154-155
 increased pH due to, 63
Barium esophagoscopy, 69-71, 70
 indications for, 71
 sensitivity and specificity of, 64, 70
Barrett's dysplasia. See also *Dysplasia*.
 cancer concurrent with, 91-92
 cancer, progression to, 86-88
 grades of, 88t
 histologic regression of, 88-89
 surveillance in, 90-91, 91t
 treatment of, 92-93
Barrett's epithelium, endoscopy in diagnosis of, 69
Barrett's esophagus. See also *Barrett's metaplasia*.
 association with GERD and esophageal cancer, 89-90
 diagnosis of, 60
 length of, 85, 93
 LESP in, 14
 as phenotypic group, 12
 progression from ERD or NERD to, 13
 progression to esophageal cancer, 89-90
 maintained healing for prevention of, 111
 risk factors for, 89-90
 as risk in symptomatic treatment of GERD, 111
 sleep disturbances and, 147
Barrett's metaplasia, 7, 79-93
 adenocarcinoma associated with, 85, 89-90
 adenocarcinoma from, 80-81
 dysplasia and, 86-88, 88t
 histologic sequence in, 86
 biopsy and, 79
 cancer and, 89-90
 adenocarcinoma, 80-81, 85, 89-90
 Helicobacter pylori infection and, 93
 risk of developing, 80-81
 cellular changes in, 81-89, 87
 diagnosis of, 84-87, 87
 dysplasia and, 45, 86-88
 cancer concurrent with, 91-92
 endoscopy in surveillance of, 90-91, 91t, 93
 endoscopy of, 81, 86
 esophageal length in, 85, 93
 gender and race in, 81
 Helicobacter pylori and, 85-86, 93
 histologic appearance of, 84, 87
 incidence of, 80
 intestinal metaplasia in, 84, 85-86

- Barrett's metaplasia (*continued*)
 nocturnal acid breakthrough in, 85, 147-148
 prevalence in GERD patients, 80
 progression from ERD or NERD to, 13
 progression from GERD, 14, 80
 association with esophageal cancer and, 89-90
 chronicity in, 81
 screening for, 81
 surveillance for, 90-91, 91t, 93
 esophagectomy as alternative to, 92
 symptoms of, 81-84
 treatment of
 ablative therapies, 92-93
 histamine₂-receptor antagonists, 85
 proton pump inhibitors, 85, 93
 regression due to, 88-89
 surgical fundoplication, 93
 vs inflammatory erosions, 79, 84
- Bed, elevation of head of, 117, 118
- Bernstein test. See *Acid perfusion (Bernstein) test*.
- Bicarbonate
 gastric, 134
 sodium bicarbonate, 128t-129t, 130
- Bile acids, 29-31
 Barrett's metaplasia and, 81
 binding with sucralfate, 134
- Biopsy, 67-69
 for Barrett's metaplasia, 93
 for *Helicobacter pylori* infection, 106t
 indications for, 69
 mucosal, sensitivity and specificity of, 64
- Bipolar coagulation ablation, 92
- Bismuth-containing compound, 106t, 107t
- Bleeding
 as complication of erosive esophagitis, 77
 endoscopy in diagnosis of, 69
- Bloating, after fundoplication surgery, 173, 174
- Blood supply, esophageal, 32, 32
- BMI, high
 esophageal adenocarcinoma risk and, 90
 as indication for surgery, 170t
 risk of GERD symptoms and, 113
- Body position. See *Posture*.
- Bravo pH Probe, 63-65
- Breast-feeding, proton pump inhibitors contraindicated during, 151
- Bronchostasis, 47t
- Bronchitis, chronic, 7, 47t
- Bronchodilators, sphincter relaxation by, 49
- Bronchospasm, reflux-induced, 50
- Caffeine, drug interaction profile, 152t
- Calcium absorption, PPIs and, 156
- Calcium carbonate, 130
- Campylobacter* infection, 155
- Cancer. See also *Adenocarcinoma of the esophagus*.
 Barrett's metaplasia and, 80-81, 89-90
 concurrent with dysplasia, 91-92
 from dysplasia, 86-88, 92
 endoscopy and biopsy in surveillance for, 90-92, 91t
 laryngeal, 47t
 in rats, proton pump inhibitor trials and, 151-154
- Carbamazepine, drug interaction profile, 152t
- Carbohydrates, low-carbohydrate diet, 115, 116
- Cardiac disorder
 Bernstein test cautions for, 71
 concomitant with GERD, 60
- Central nervous system, H₂-RA effects on, 134
- Cephalic phase of acid secretion, 123t, 124
- Chest pain, 48-49
 association with GERD, 44
 noncardiac (NCCP), 48-49
- Chief cells, 121
- Chocolate, LESP reduction by, 24, 114
- Cholinergic reflexes, 124, 125
- Cigarette smoking. See *Smoking*.
- Cimetidine (Tagamet), 131-134. See also *Histamine₂-receptor antagonists*.
 adverse effects, 134
 chemical structure, 132
 dosage, 126t, 133-134
 high-dose, 133-134
 drug interactions, 133
 efficacy, 133-134
 compared with other agents, 135
 indications for, 126t
- Cinacalcet, drug interaction profile, 152t
- Circadian cycle, pH monitoring over, 66
- Circadian rhythm, of basal acid secretion, 124
- Clearance. See *Esophageal clearance*.
- Clinical Outcomes Research Initiative (CORD), data on GERD and esophagitis, 11-12
- Clinical presentations of GERD, 11-12, 13-14
- Clostridium difficile*-associated disease, 154-155
- Coagulation ablation, for dysplasia, 92
- Coffee, 24, 115
- Collagen denaturation (Stretta procedure), 171t, 176, 177
- Collis gastroplasty, 171, 171t
- Columnar epithelium. See *Epithelium*.
- Community-acquired pneumonia, 154-155
- Complications of GERD, 77-96. See also *specific complication, eg, esophagitis*.
 barium esophagoscopy in diagnosis of, 71
 endoscopy in diagnosis of, 69
 erosive/ulcerative esophagitis, 77, 78
 esophageal strictures, 77-79, 79
 gastric hypersecretion, 31, 172
 LES defects and, 30, 30
 pyloric sphincter defect and, 29-30, 30
 sleep disturbances as cause of, 147
- Constipation
 as side effect of antacids, 130
 as side effect of PPIs, 150
 as side effect of sucralfate, 134

Continuum model of GERD, 12
Coronary disease, cautions for acid perfusion (Bernstein) test, 71
Cost, of heartburn remedies, 7
Cough, 47t, 50-53
 chronic, 50-53
 GERD-induced, 7
 pH monitoring in, 63
 in ProGERD study, 48
Crural diaphragm
 anatomy of, 20, 21
 hiatal hernia and, 35
 sphincteric functions and, 24
Cyclosporin, drug interaction profile, 152t
Cytochrome P-450 enzyme system, in proton pump inhibitor metabolism, 150

Death
 from GERD, 14
 from idiopathic pulmonary fibrosis, 53
DeMeester score, 170t
Dental infection, 62
Diagnosis of GERD, 59-75
 acid perfusion (Bernstein) test, 71
 barium esophagoscopy, 69-71, 70
 biopsy, 67-69
 diagnostic tests, 60-61
 sensitivity and specificity of, 64
 endoscopy with biopsy, 67-69
 esophageal body manometry, 65-66
 combined with pH monitoring, 66-67, 68-69
 LES manometry, 65, 66
 motility monitoring, 60
 pH monitoring, prolonged, 61-65, 62t, 64
 radionuclide studies, 62
 therapeutic trials in, 59-60
 in young patients, 60

Diaphragm
 crural, anatomy of, 20, 21
 hiatal hernia and, 34-35
 role in LES and reflux prevention, 27-29, 34
 sliding hernia and, 34

Diarrhea
 as side effect of antacids, 130
 as side effect of fundoplication, 174
 as side effect of H₂-RAs, 134
 as side effect of PPIs, 149, 150

Diazepam, proton pump inhibitor interaction with, 152t
Diclofenac, proton pump inhibitor interaction with, 152t
Dietary restriction/modification, 112t, 113-115
Digestion of nutrients, gastric acid inhibition and, 155
Digoxin, proton pump inhibitor interaction with, 152t
Diverticula, esophageal, barium esophagoscopy in diagnosis of, 71
Dizziness, as side effect of PPIs, 150
Doxycycline hyclate, stricture induced by, 82t-83t
Drugs
 associated with GERD symptoms, 112t, 117-118
 bioavailability of, 133, 150-151

Drugs (*continued*)
 drug-induced esophageal strictures, 77-78, 80, 82t-83t
 interactions, 122t
 cimetidine, 133
 PPIs, 150-151, 152t-153t
 proper ingestion technique for, 117
 Dry mouth, as side effect of PPIs, 150
 Duodenal juice, combined with gastric acid, 30-31
 Duodenal reflux, 29-31
 Dyspepsia, in Barrett's metaplasia, 84
 Dysphagia, 45
 adenocarcinoma and, 85, 86-88, 88t, 89
 after fundoplication surgery, 174-176
 diagnosis of, 46, 60
 endoscopy in, 69
 nonobstructive, 45
 strictures and, 45, 79
 as symptom of GERD, 45
 Dysplasia, 86-89
 cancer concurrent with, 91-92
 cancer, progression to, 86-88, 92
 definition of, 86
 grades of, 88t
 regression of, 88-89
 surveillance in, 90-92, 91t
 treatment of
 endoscopic ablation therapies, 92-93
 esophagectomy in, 92
 proton pump inhibitors, 93
ECL cell hyperplasia, 151-154
EE. See *Erosive esophagitis*.
Elevation of head of the bed, 112t, 117, 118
ELGP method (EndoCinch), 171t, 176
EndoCinch (Bard), 171t, 176, 177
Endocrine receptors, 121
Endoscopic therapies, 171t, 176-177
 ablation therapies for dysplasia, 92-93
 bulking injection methods
 Enteryx Procedure, 176-177
 Gatekeeper Reflux Repair System, 176-177
 plicating gastric fold methods
 EndoCinch, 171t, 176, 177
 Endoscopic Suturing Device, 176
 Full-Thickness Plicator, 171t, 176
 radiofrequency energy collagen denaturation (Stretta procedure), 171t, 176, 177
Endoscopy, 67-69. See also *Endoscopic therapies*.
 in Barrett's metaplasia, 90-91, 91t
 ablative therapies, 92-93
 esophagitis severity determination with, 67
 for *Helicobacter pylori* infection, 106t
 indications for, 67-69
 sensitivity and specificity of, 64
Enteric infections, 154-155

- Enterooxynin, 123t
- Enteryx Procedure (Boston Scientific), 176-177
- Epidermal growth factor, 134
- Epithelium
of esophagus
in Barrett's metaplasia, 81-85, 86-87, 92
as defense to reflux, 31-32, 32
effects of reflux on, 31-32, 33
stem cells in, 81, 151
of stomach, gastric acid secretion and, 121-124, 125
- ERD (erosive reflux disease). See also *NERD (nonerosive reflux disease)*
atypical symptoms in patients with, 47-49
LESP in, 14
progression/regression of, 12, 13
- Erosion of gastroesophageal junction, 84
- Erosive esophagitis (EE), 77. See also *Esophagitis*.
association with GERD, 44
drugs for, 126t-129t
endoscopic appearance of, 78
as phenotypic group, 12
PPI therapy for, 137-138, 138, 156-159
symptom relapse rates, 169
sleep disturbances and, 147
strictures associated with, 77-79, 79
- Erosive reflux disease. See *ERD (erosive reflux disease)*.
- Esomeprazole (Nexium), 138, 156-157
bioavailability, 150-151
chemical structure, 139
comparison with other PPIs, 142, 143, 144-145
dosage, 127t, 156-157
drug and food interactions, 150-151, 152t-153t
efficacy, 142, 143
maintenance therapy, 144-145
for nocturnal acid breakthrough, 148
formulations, 138, 156-157
indications for, 127t, 156-157
ProGERD study, 13
side effects, 150
- Esophageal body, manometry of, 65-67, 68-69
- Esophageal clearance, 25-29
delayed, 26
gravity and, 27
head elevation and, 112t, 117, 118
hiatal hernia and, 28-29
impaired, 26-29
intra-abdominal anchorage and, 27-29
motor events (defective) during, 26-27
nocturnal, 25
peristalsis and, 21, 23, 26, 27
posture and, 26, 112
salivation and, 27
- Esophageal damage, cause of, 7
- Esophageal hypersensitivity, 25
- Esophageal motility
ambulatory monitoring of, 60
with pH monitoring, 60
- Esophageal motility (*continued*)
Helicobacter pylori infection and, 98
surgical considerations, 175
- Esophageal motor events during reflux, 21, 22
- Esophageal mucosa, 32
biopsy of, 64
tissue barrier integrity, 31-32, 32
- Esophageal pathology, incidence of, 7
- Esophageal pH, prolonged monitoring of, 61-65. See also *pH*.
- Esophageal sensitivity, 44
- Esophageal sphincter, lower. See *Lower esophageal sphincter (LES)*.
- Esophageal strictures. See *Strictures, esophageal*.
- Esophageal tissue barrier, 20, 31-32, 32
- Esophagectomy, 92
- Esophagitis
aspirin and, 118
Barrett's metaplasia and, 80
endoscopy of, 67-69, 78
erosive, 12, 77
bleeding as complication of, 77
drugs for, 126t-129t
endoscopic appearance of, 78
as phenotypic group, 12
progression to Barrett's metaplasia, 80
sleep disturbances and, 147
strictures associated with, 77-79, 79
healing, as therapeutic goal, 111
Helicobacter pylori infection as protection against, 97-98
incidence of, 7, 67
LES mechanical failure/defects and, 24, 33-34
nocturnal reflux and, 25
prevalence of, 12
proton pump inhibitors for, 137-138
smoking and, 115-116
treatment of, 126t-129t, 137-138, 138, 156-159
symptomatic treatment, risks involved, 111
ulcerative, LES in, 14
- Esophagoscopy, barium. See *Barium esophagoscopy*.
- Esophagus
Barrett's. See *Barrett's metaplasia*.
blood supply of, 32, 32
manometry of, 65-67, 68-69
motor activity, defective, 26-27
motor events during acid reflux, 21, 22
- Esophagus See *Esophageal entries*.
- Ethanol. See also *Alcohol*.
lower esophageal sphincter pressure and, 24
proton pump inhibitor interaction profile, 152t
- Exercise, 115
- Famotidine (Pepcid), 131-134. See also *Histamine₂-receptor antagonists*.
chemical structure, 132
dosage, 126t
Maximum Strength Pepcid AC, 131
indications for, 126t

Fat, body. See *BMI; Obesity*

Fat, dietary

- esophageal acid exposure and, 114
- high-fat vs low-fat diet, 114
- LESP reduction by, 24, 114

Fiber, dietary, 115

Fibrosis

- idiopathic pulmonary, 53
- strictures and, 77

FINBAR study, 90

Flatulence, as side effect of PPIs, 149, 150

Food intake

- before bedtime, 113
- foods to avoid, 24, 114
- lower esophageal sphincter pressure and, 24, 114
- meal size, 113-114
- restriction of, 113-115
- supine position after, 112-113

Fracture risk, 155-156

Full-Thickness Plicator (NDO Surgical), 171t, 176

Fundoplication, 171t, 172-176

- adverse events, postsurgical, 173-175
- for Barrett's metaplasia, 93
- failure of, 175-176
- long-term outcomes, 173-175
- for NERD patients, 172-173
- for paraesophageal hernia, 34-35
- types of
 - laparoscopic vs open, 171, 171t, 172, 173-175
 - Nissen 360-degree, 170-171, 171t, 172, 173-175, 176
 - Toupet 270-degree, 170-171, 171t, 174, 175

G cells, 121, 123t, 125

Gastric acid

- acid pump, inhibitors of. See *Proton pump inhibitors*.
- enteric infection and, 154-155
- excess, 7
- hypersecretion of, 31, 172
- inhibitors of. See *Pharmacologic management of GERD*.
- long-term suppression, safety of, 151-156
- nocturnal secretion of, 124
- perfusion of, 26
- pH of. See also *Pharyngoesophageal pH*.
- regurgitation of, 43-44, 59
- secretion of, 121-124, 125, 135
 - acid pump and, 121, 135-136, 136
 - basal, 124
 - phases of, 121-124, 123t
 - potential stimulation by antacids, 130

Gastric acid suppression therapy. See *Acid-suppression therapy*.

Gastric cardia, metaplasia of, 85-86

- Helicobacter pylori* infection and, 85-86

Gastric distention, 29, 114

- causes of, 29
- parietal cell activation by, 124, 125

Gastric distention (*continued*)

- reflux and, 29
- TLESRs in response to, 23

Gastric emptying, 133

- delayed/slow, 19, 29

Gastric folds, surgical procedures, 171t, 176-177

Gastric hypersecretion, 31, 172

Gastric hypochlorhydria, 62, 156

Gastric phase of acid secretion, 123t, 124, 125

Gastric sling, 20, 21, 24

Gastric volume, 29

- dietary restriction in reduction of, 113-114
- TLESRs and, 29

Gastrin, 121, 123t, 125

- antacids and, 130
- Helicobacter pylori* infection and, 101, 102
- receptors, 121, 125
- site of action on parietal cell, 136

Gastritis

- Helicobacter pylori* infection and, 103-104
- increased risk of with long-term acid suppression and *H pylori* infection, 97-99, 102

Gastroduodenal reflux, 29-31

Gastroesophageal junction (GEJ)

- anatomy of, 20-21, 21
- erosion of, 84
- incompetence of, two sphincter hypothesis, 34
- surgical procedures and, 171, 172t

Gastroesophageal reflux

- definition of, 7
- motor events during, 21, 22
- normal occurrence of, 19
- progression to GERD. See *Pathophysiology of GERD*.

Gastroesophageal reflux disease (GERD)

- overview, 7-9
- pathophysiology. See *Pathophysiology of GERD*.
- phenotypic model of, 12-13
- pyramid of associated diseases, 44
- spectrum-continuum model of, 12

Gastroesophageal scintiscanning, 64

Gastroplasty, Collis, 171t

Gatekeeper Reflux Repair System (Medtronic), 176-177

Gender

- adenocarcinoma and, 81
- Barrett's metaplasia and, 81
- NERD vs EE characteristics and, 12

Glibenclamide, proton pump inhibitor interaction profile, 152t

Globus, 47t, 50, 51

Goblet cells, 84

Gravity, esophageal clearance and, 27

Gynecomastia, 134

H⁺/K⁺-ATPase acid pump, 121, 135-136, 136

- inhibition, mechanisms of, 135-136
- inhibitors of, 127t-129t, 135-159. See also *Proton pump inhibitors*.

- H₂-blockers, yearly dollars spent on, 7
- H₂-RAs. See *Histamine₂-receptor antagonists*.
- Headache
- as side effect of H₂-RAs, 134
 - as side effect of PPIs, 149
- Heartburn, 43
- antacids for, 130
 - drugs for, 126t-129t, 130
 - foods triggering, 24, 114
 - incidence of, 7, 43
 - meal size and, 113-114
 - posture and, 43
 - in pregnancy, 43
 - proton pump inhibitors for, 137
 - timing of, 43
- Helicobacter pylori* infection, 97-109
- atrophic corpus gastritis and, 97, 103-104
 - Barrett's metaplasia and, 85-86, 93
 - diagnostic tests for, 104-105, 106t-107t
 - effects of, explanation and flow chart, 101, 102
 - gastritis and, 154
 - GERD and, 97-101, 102
 - acid-suppression therapy and, 97-98, 99-101, 100
 - geographical differences in, 98-99
 - prevalence of *H pylori* infection in, 98
 - protective role of *H pylori* in, 97-98, 99
 - intestinal metaplasia and, 85-86
 - prevalence of, 98-99
 - proton pump inhibitor enhancement by, 97-98, 99-100, 100
 - screening for, 104-105, 106t-107t
 - treatment recommendations for, 101, 104
- Hiatal hernia, 7, 32-35, 35
- association with GERD, 33
 - barium esophagoscopy in diagnosis of, 71
 - as caused by gastroesophageal reflux, 35
 - esophageal clearance and, 28-29
 - incidence of, 32
 - lower esophageal sphincter pressure and, 33-34, 35
 - paraesophageal, 34-35
 - presence in NERD vs EE, 12
 - reduced esophageal clearance and, 28-29
 - sliding, 33, 34
 - surgical procedures for, 34-35, 172t, 177
 - types of, 32-33
- Hip fracture risk, 155-156
- Histamine/histamine receptors, 121, 125, 131-132, 135
- Histamine₂-receptor antagonists (H₂-RAs), 112t, 131-134. See also *specific agents*.
- action mechanisms, 124, 131-133
 - adverse effects, 134
 - for Barrett's metaplasia, 85
 - as bedtime add-on to other medication, 53, 147, 148
 - bioavailability, 133
 - chemical structures, 132
- Histamine₂-receptor antagonists (H₂-RAs) (*continued*)
- dosage, 126t, 133-134
 - high-dose, 133-134
 - OTC vs prescription strength, 131
 - effects of, compared with other agents, 122t
 - efficacy
 - compared with other agents, 122t, 133, 137, 144
 - comparison of H₂-RA agents, 133
 - fracture risk, negative, 156
 - generic formulations, 131
 - indications for, 126t
 - for nocturnal reflux, 132, 147
 - for patients with atypical symptoms, 53
 - site of action, 136
 - specific agents, 126t, 131
 - strength of, 131, 133-134
 - yearly dollars spent on, 7
- Hoarseness, 47t, 50, 51
- pH monitoring in, 63
- Hormones
- gastric, *Helicobacter pylori* infection and, 101, 102
 - LESP increase due to, 23
- Hot liquid sensitivity, 44
- Hydrochloric acid, secretion in stomach, 121-124, 125, 135
- Hypercalcemia, antacids and, 130
- Hyperchlorhydria, 151
- Hypergastrinemia, 151-154
- Hypersecretion of gastric acid, 31, 172
- Hypersensitivity, esophageal, 25
- Hypochlorhydria, 62, 156
- Idiopathic pulmonary fibrosis (IPF), 53
- Immunoglobulin G, serology for, 106t
- Impaction of food, 77
- Impedance monitoring, multichannel, 66-67, 68-69
- Impotence, 134
- Infection
- dental, 62
 - enteric, 154-155
- Inflammation
- Barrett's metaplasia from, 81
 - Barrett's metaplasia vs., 79, 84
 - chronic, nocturnal reflux and, 52-53
- Intestinal metaplasia, 84, 85-86
- Intestinal phase of acid secretion, 123t, 124
- Intra-abdominal anchorage, loss of, 27-29
- Intra-abdominal pressure, 29
- esophageal clearance and, 29
 - hiatal hernia and, 34
- IPF (idiopathic pulmonary fibrosis), 53
- Iron salts, PPI effect on bioavailability of, 150
- Ketoconazole, PPI effect on bioavailability of, 150

- Lactation, proton pump inhibitor use during, 151
- Lansoprazole (Prevacid), 138, 157
 - bioavailability, 150-151
 - chemical structure, 139
 - dosage, 127t, 157
 - drug and food interactions, 150-151, 152t-153t
 - efficacy, 140-141
 - for nocturnal acid breakthrough, 148
 - formulations, 138, 157
 - Helicobacter pylori* infection and, 103
 - indications for, 127t, 157
 - long-term safety, 151-154
 - in pregnancy, 151
 - side effects, 149
 - symptom relief with, 140-141
- Laparoscopic fundoplication, 171t, 172-176. See also *Fundoplication*.
- Laryngeal cancer, 47t. See also *Cancer*.
- Laryngeal epithelium, gastric juice contact with, 52-53
- Laryngeal lesions, 51
 - pharyngoesophageal pH monitoring in, 52
- Laryngitis/laryngeal symptoms, GERD and, 7, 47t, 50-53
 - reflux laryngitis (LPR), 51
- Laser therapy, for dysplasia, 92
- Leg lift, in hiatal hernia, 34
- LES. See *Lower esophageal sphincter*.
- LESP. See *Lower esophageal sphincter, pressure of*.
- Levothyroxine, proton pump inhibitor interaction profile, 153t
- Lifestyle changes, 112-118, 112t. See also *Nonpharmacologic management of GERD*.
- Lower esophageal sphincter (LES), 20-25
 - anatomy of, 20-21, 21
 - functions of, 20
 - integrity of
 - compromised in GERD, 7, 20
 - compromised, severity of complications and, 30, 30
 - obesity and, 21, 113
 - length of, 24-25, 65
 - manometry of, 65, 66
 - sensitivity and specificity of, 64
 - mechanical failure of, 23-24
 - motor events during acid reflux, 22
 - myogenic failure of, 23
 - pressure of (LESP), 14, 21, 98
 - factors affecting, 23-24
 - foods affecting, 24, 114
 - gastric pH and, 124
 - hiatal hernia and, 33-34, 35
 - inadequate, mechanical failure of LES and, 23
 - manometric determination of, 65
 - in NERD vs other conditions, 12, 14
 - resting, 21
 - in severe GERD, 24
 - smoking and, 115
 - surgical procedures and, 171, 172t
 - role of, 20-21
 - swallowing, relaxation during, 21, 22
- Lower esophageal sphincter (LES) (*continued*)
 - tone of, 21, 23-24
 - transient relaxations of (TLESRs), 22-23, 26
 - gastric volume and, 29
 - neural mediation of, 23
 - in pathophysiology of GERD, 20
 - surgical procedures and, 171, 172t
- LPR (reflux laryngitis), 51
- Magnesium hydroxide, 130
- Management of GERD
 - endoscopic ablative therapies, 92-93
 - goal of, 111
 - nonpharmacologic. See *Nonpharmacologic management of GERD*.
 - in patients with atypical symptoms, 53, 60
 - pharmacologic. See *Pharmacologic management of GERD*.
 - phases of, 111, 112t
 - surgical. See *Surgical management of GERD*.
 - therapeutic end points of, 111
 - therapeutic trials, as part of diagnosis, 45, 59-60
 - in young patients, 60
- Manometry
 - combined with pH monitoring, 66-67, 68-69
 - of esophageal body, 65-66
 - of lower esophageal sphincter, 65, 66
 - sensitivity and specificity of, 64
- Meal size, 113-114
- Medications. See *Drugs; specific drugs*.
- Metaplasia
 - Barrett's. See *Barrett's metaplasia*.
 - intestinal, 84, 85-86
- Metoprolol, proton pump inhibitor interaction profile, 153t
- Monitoring, pH. See *pH, esophageal, monitoring of*.
- Mortality from GERD, 14
- Motility, esophageal. See *Esophageal motility*.
- Motor function
 - barium studies in diagnosis of, 71
 - esophageal, defective, 26-27
 - events during reflux, 21, 22
- Mucosa, esophageal, 31-32, 32, 64
- Müller's maneuver, 34
- Multichannel impedance monitoring, 66-67, 68-69
- Muscarinic receptors, 121
- Naproxen, proton pump inhibitor interaction profile, 153t
- Natural history of GERD, 11-17
 - continuum vs phenotypic models, 12-13
 - progression/regression of conditions, 12-13
- Nausea, as side effect of PPIs, 149-150
- NCCP (noncardiac chest pain), 48-49
- NERD (nonerosive reflux disease)
 - association with GERD, 44
 - atypical symptoms in patients with, 47-49
 - diagnosis of, 61
 - Helicobacter pylori* infection and, 99, 102

NERD (nonerosive reflux disease) (*continued*)

- LESP in, 14
- as phenotypic group, 12-13
- PPI therapy for, 137-138, 138, 146
 - amount of symptom control with, 169
 - progression/regression of, 12, 13
 - surgical procedures for, 170t, 172-173

Nexium. See *Esomeprazole*.

Nifedipine, proton pump inhibitor interaction profile, 153t

Nissen fundoplication, 170-171, 171t, 172, 173-175

- for reintervention, 176

Nizatidine (Axid), 131-134. See also *Histamine₂-receptor antagonists*.

- chemical structure, 132
- dosage, 126t
- efficacy, 143
- indications for, 126t

Nocturnal acid breakthrough, proton pump inhibitors and, 147-149

Nocturnal acid secretion, 124

- H₂-RA inhibition of, 132

Nocturnal reflux, 25, 147

- in Barrett's metaplasia, 85, 147-148

- esophageal clearance and, 25

- H₂-RA inhibitors and, 132, 147

- head of bed, elevation and, 117, 118

- Helicobacter pylori* infection and, 99

- otolaryngologic symptoms and, 52

- proton pump inhibitor effectiveness for, 147-149

Noncardiac chest pain (NCCP), 48-49

Nonerosive reflux disease. See *NERD (nonerosive reflux disease)*.

Nonpharmacologic management of GERD, 111-120, 112t

- alcohol, 117
- dietary restriction/modification, 113-115
- drugs, ingestion and use considerations, 117-118
- elevation of head of bed, 117, 118
- posture/supine position, 112-113
- smoking, 115-116
- weight loss/obesity, 113

Nonsteroidal anti-inflammatory drugs (NSAIDs), 117-118

NSAIDs (nonsteroidal anti-inflammatory drugs), 117-118

Nutrient digestion/absorption, 155

Obesity, 113

- esophageal adenocarcinoma risk and, 90

- GERD symptoms and, 113

- increased intragastric pressure and, 21

- low-carbohydrate diet, 115, 116

- low-fat diet, 114

- lower esophageal sphincter function and, 21, 113

Obstruction, esophageal, 63

Obstructive sleep apnea syndrome, 45

Odynophagia, 44

- stricture and, 77

Omeprazole (Prilosec), 138-140, 157-158. See also *Omeprazole/sodium*

- bicarbonate (Zegerid)*.

- chemical structure, 139

- comparison with other PPIs, 141-142, 144

Omeprazole (Prilosec) (*continued*)

- diagnostic trial of, 59

- dosage, 127t, 157-158

- drug and food interactions, 151, 152t-153t

- efficacy, 140-142

- maintenance therapy, 144

- for nocturnal acid breakthrough, 148-149

- formulations, 138-140, 157-158

- Helicobacter pylori* infection and, 103-104

- indications for, 127t, 157-158

- long-term safety, 151, 154

- in pregnancy, 151

- side effects, 149, 150

Omeprazole/sodium bicarbonate (Zegerid), 140, 158. See also *Omeprazole (Prilosec)*.

- dosage, 128t-129t, 158

- indications for, 128t-129t, 158

- for nocturnal acid breakthrough, 148-149

Oral contraceptives, proton pump inhibitor interaction with, 152t

Oral epithelium, gastric juice contact with, 52

Orodenal erosions, 45, 47t

Otitis, 47t

Otolaryngologic manifestations of GERD, 47t, 50-53. See also *Asthma*.

- diurnal fluctuation in, 52

Otolaryngologic symptoms, association with GERD, 44

Oxyntic glands, 121

Pantoprazole (Protonix), 140, 158-159

- chemical structure, 139

- comparison with other PPIs, 141-143, 144-145

- dosage, 129t, 158-159

- drug interaction profile, 152t-153t

- efficacy, 141-143

- Helicobacter pylori* infection and, 99-100, 100

- maintenance therapy, 144-145

- for nocturnal acid breakthrough, 149

- on-demand treatment, 146-147

- indications for, 129t, 158-159

- intravenous, 159

- in pregnancy, 151

- side effects, 149-150

Paracrine cells and receptors, 121

Paraesophageal hernia, 34-35

Parietal cells, 121

- action of antisecretory agents on, 136

- activation/stimulation of, 121-124, 125, 135

- phases/initiators/paths/mediators, 123t, 124, 125

- proton pump inhibitors and, 135-136

- receptors on, 121, 125

Pathophysiology of GERD, 19-41

conditions relating to severity, 19

contributory factors, 20

esophageal clearance, 25-29

esophageal hypersensitivity, 25

esophageal tissue barrier, 31-32, 32-33

Pathophysiology of GERD (*continued*)

- gastric hypersecretion, 31
- gastric volume/distention, 29
- gastroduodenal reflux, 29-31
- hiatal hernia, 32-35, 35
- intra-abdominal pressure, 29
- lower esophageal sphincter relaxation/dysfunction in, 20-25
- nocturnal reflux, 25
- unaltered by acid reduction treatments, 14

Pepcid. See *Famotidine*.

Peppermint, LESP reduction by, 24, 114

Pepsin, 29, 31, 121, 130

- antacids and, 130
- sucralfate binding of, 134

Pepsinogen, 121

Peptic cells, 121

Peptic strictures, 77, 111

Peptic ulcer disease, diagnosis of, 59-60

Peptides, 23, 121, 123t

Peristalsis, 21, 22

- acid clearance by, 21, 22, 23, 26
- alcohol and, 117
- experimental abolishment of, 26
- inadequate, dysphagia and, 45
- manometric measurement of, 65-66
- secondary waves, 27

pH

- esophageal
 - bacterial overgrowth and, 63
 - in diagnosis with atypical symptoms, 45
 - maintenance after acid reflux, 23
 - monitoring of, 52, 61-65
 - combined with manometry (impedance monitoring), 66-67, 68-69
 - false-negative results, 62-63
 - guidelines for, 61
 - sensitivity and specificity of, 64
 - variables measured, 62, 62t
 - wireless device for, 63-65
 - salivation and, 25
- gastric
 - antacids and, 124, 130
 - drug absorption/bioavailability and, 150-151
 - proton pump inhibitors and, 135-136
- Helicobacter pylori* infection and, 97, 101
- pharyngoesophageal, 52, 61-66
- salivary, 25
- dental infection and, 62

Pharmacologic management of GERD, 14, 112t, 121-168. See also *specific agents*.

- Helicobacter pylori*, acid suppression therapy and, 97-98, 99-101, 100, 103-104
- physiology of acid secretion/regulation, 121-125, 123t, 125
- rationale for, 121
- remission without, 11

Pharmacologic management of GERD (*continued*)

- specific agents, 126t-129t
 - acid pump inhibitors. See *Proton pump inhibitors*.
 - alginic acid, 131
 - antacids, 124, 130
 - comparison of effects of, 122t
 - histamine₂-receptor antagonists. See *Histamine₂-receptor antagonists*.
 - NSAIDs, 117-118
 - proton pump inhibitors. See *Proton pump inhibitors*.
 - sites of action, 136
 - sucralfate, 134-135
 - symptom return after discontinuance of, 14
 - unsatisfactory symptom control with, surgical alternatives, 169, 170, 170t
- Pharyngeal epithelium, gastric juice contact with, 52-53
- Pharyngitis, 47t
- Pharyngoesophageal pH, monitoring of, 52, 61-66. See also *pH*.
- Phenazone (antipyrene), 152t
- Phenotypic model of GERD, 12-13
- Phenprocoumon, proton pump inhibitor interaction profile, 153t
- Phenytoin
 - proton pump inhibitor interaction profile, 153t
 - stricture induced by, 82t
- Photodynamic therapy, 92
- Phrenoesophageal ligament, 21, 28
- Piroxicam, proton pump inhibitor interaction profile, 153t
- Plication surgeries, 171t, 176-177
- Pneumonia
 - aspiration, 47t
 - community-acquired, 154-155
- Postprandial reflux, 7, 59
 - LES length and, 24-25
 - severity of, diet and, 113-114
- Postprandial secretory response, 124
- Posture
 - acid regurgitation and, 26, 59
 - after meals, 112-113
 - heartburn and, 43
 - supine reflux, 24, 26, 112, 117
- Potassium chloride, stricture induced by, 82t
- PPIs. See *Proton pump inhibitors*.
- Pregnancy
 - heartburn in, 43
 - proton pump inhibitors in, 151
- Prevacid. See *Lansoprazole*.
- Prevalence of esophagitis, 12
- Prilosec. See *Omeprazole*.
- ProGERD study, 13
 - atypical symptoms in, 45-50
- Prostaglandins
 - gastric, 134
 - synthetic, site of action of, 136
- Proton pump inhibitors (PPIs), 112t, 135-159. See also *specific agents*.
 - action mechanisms, 124, 135-136, 136
 - for Barrett's metaplasia, 85, 93
 - chemical structures, 139

Proton pump inhibitors (PPIs) (*continued*)

- comparisons among, 138-149
- decrease in strictures correlated with use, 78, 79
- diagnostic trial of, 45, 59-60
- dosage, 127t-129t, 156-159
- drug and food interactions, 122t, 150-151, 152t-153t
- effects of, compared with other agents, 122t
- efficacy, 137-149, 138
 - compared with other agents, 122t, 133, 137, 144
 - comparison of PPIs, 138-149
 - Helicobacter pylori* infection enhancement of, 97-98, 99-100, 100
 - maintenance therapy, 143-146
 - on-demand treatment, 146-147
- as first-line therapy for GERD, 137
- half-life, 136-137
- indications for, 127t-129t, 156-159
- long-term use
 - Helicobacter pylori* infection and atrophic gastritis risk in, 98, 103-104
 - long-term maintenance therapy, 145-146
 - safety of, 151-156
 - nocturnal acid breakthrough and, 147-149
 - pH monitoring and, 61, 67, 68-69
 - in pregnancy and lactation, 151
 - response rate in NERD vs EE, 12
 - safety, long-term, 151-156
 - tumor incidence with use in rats, 151-154
 - side effects, 149-150
 - site of action, 136
 - specific agents, 127t-129t
 - unsatisfactory control with, surgical alternatives, 169, 170, 170t
 - vs other agents, 122t
 - yearly dollars spent on, 7

Protonix. See *Pantoprazole*.

Protoporphyrin-based photodynamic therapy, 92

Pulmonary fibrosis, idiopathic, 53

Pulmonary symptoms associated with GERD, 47t

Pyloric sphincter, incompetent, 29

Quality of life, 169, 170

Quinidine, stricture induced by, 83t

Rabeprazole (Aciphex), 140, 159

- chemical structure, 139
- comparison with other PPIs, 141-142, 144
- dosage, 129t, 159
- drug interaction profile, 152t-153t
- efficacy, 141-142
 - maintenance therapy, 144
 - long-term, 145-146
- Helicobacter pylori* infection and, 104
- indications for, 129t, 159
- long-term safety, 154
- side effects, 149-150
- symptom relief, 142
- time of action, 141

Race, Barrett's metaplasia and, 81

Radiofrequency energy collagen denaturation (Stretta procedure), 171t, 176, 177

Radionuclide imaging, diagnostic, 62

Radiotherapy, reduced salivation and, 27

Ranitidine (Zantac), 131-134. See also *Histamine₂-receptor antagonists*.

- chemical structure, 132
- diagnostic trial of, 59
- dosage, 126t, 131
- efficacy, 134, 135
- indications for, 126t
- Maximum Strength Zantac, 131

Reflux, gastroduodenal, 29-31

Reflux, gastroesophageal. See *Gastroesophageal reflux*.

Reflux disease. See *ERD (erosive reflux disease)*; *Gastroesophageal reflux disease (GERD)*; *NERD (nonerosive reflux disease)*.

Reflux laryngitis (LPR), 51

Regurgitation of gastric acid, 43-44, 59

- persistent, surgery and, 170t, 177

Remission, spontaneous, 11

ReQuest/ReQuest GI questionnaire, 143

Respiratory disorders, 47t, 48, 147

- concomitant, 60

Risk factors

- for atrophic gastritis, 97-99, 102, 103-104
- for Barrett's esophagus, 89-90
- for cancer, 80-81, 90
- for esophageal adenocarcinoma, 90

Risk of fractures, proton pump inhibitors and, 155-156

Salivation

- decreased, 27
 - in nocturnal reflux, 25
- esophageal pH/acid clearance and, 25, 26
- hypersalivation
 - in response to acid, 27, 28
 - as symptom of GERD, 44
- sleep/nocturnal reflux and, 25

Salmonella infection, 155

Salt intake, 114

Scintiscanning, 64

Scleroderma, barium X-ray of, 70

Serotonin, 121

Sex. See *Gender*.

Sinusitis, 47t

Sjögren's syndrome, 27

Sleep

- apnea, 45, 47t
- nocturnal acid breakthrough in, 147
- disturbances
 - as cause of complications, 147
 - due to GERD, 45
- esophageal clearance and, 25, 27, 112

Smoking, 115-116

- atypical symptoms associated with, 47-48
- esophageal adenocarcinoma and, 90

- Smoking (*continued*)
- GERD and, 112t, 115-116
 - salivation and, 27
- Sodium bicarbonate, 130. See also *Omeprazole/sodium bicarbonate*.
- Somatostatin, 121
- Spasm (bronchospasm), 50
- Sphincter, lower esophageal. See *Lower esophageal sphincter (LES)*.
- Spontaneous remission, 11
- Squamous mucosa, reflux effects on, 32-33, 33
- Stem cells, 81, 151
- Stomach. See also *Gastric entries*.
- lower esophageal sphincter position in relation to, hernias and, 34
 - plication surgeries, 171t, 176-177
 - secretory anatomy of, 121-124, 125
- Stretta procedure, 171t, 176, 177
- Strictures, esophageal, 7, 77-79, 79
- barium esophagoscopy of, 72
 - drug-induced, 77-78, 80, 82t-83t
 - endoscopy in diagnosis of, 69
 - exudate from, 78-79
 - incidence of, 78
 - length of, 77
 - NSAID-induced, 117
 - presenting complaints, 77
 - prevalence of, 12
 - recurrence after treatment, 78-79
 - treatment of, 78
- Strictures, peptic, 77, 111
- Sucralfate, 112t, 134-135
- action mechanisms, 124, 134
 - adverse effects, 134-135
 - drug interactions, 122t
 - effects of, 122t
 - efficacy, 135
 - vs other agents, 122t
- Supine reflux, 24, 26, 112
- alcohol and, 117
- Surgical management of GERD, 112t, 169-182
- candidate selection for, 169-170, 170t, 177-178
 - clinical perspective, 177-178
 - Collis gastroplasty, 171, 171t
 - effectiveness of, 171, 172, 177
 - endoscopic therapies, 171t, 176-177
 - bulking injection methods
 - Enteryx Procedure (Boston Scientific), 176-177
 - Gatekeeper Reflux Repair System (Medtronic), 176-177
 - plicating gastric folds
 - EndoCinch (Bard), 171t, 176, 177
 - Endoscopic Suturing Device (Wilson-Cook Medical), 176
 - Full-Thickness Plicator (NDO Surgical), 171t, 176
 - radiofrequency energy collagen denaturation (Stretta procedure, Curon Medical), 171t, 176, 177
 - esophageal motility and, 175
 - fundoplication, 171t, 172-176
 - adverse events, 173-175
 - for Barrett's metaplasia, 93
- Surgical management of GERD, fundoplication (*continued*)
- failure of, 175-176
 - laparoscopic vs open, 171, 171t, 172, 173-175
 - long-term outcomes, 172-175
 - Nissen 360-degree, 170-171, 171t, 172, 173-175
 - for paraesophageal hernia, 34-35
 - Toupet 270-degree, 170-171, 171t, 174, 175
 - indications for, 170t
 - mechanisms of action of, 171, 172t
 - for patients with atypical symptoms, 53
 - personnel and facilities for, 178
 - procedures in, 170-176, 171t
 - role of, 169
 - stricture resolution after, 111
- Suturing Device, Endoscopic, 176
- Swallowing, lower esophageal sphincter relaxation during, 21
- Symptomatic treatment of GERD, risks involved, 111
- Symptoms of GERD, 7, 43-58, 44
- acid regurgitation, 43-44, 59
 - atypical, 45-53, 47t
 - from associated diseases, 43, 44
 - asthma, 49-50
 - chest pain, 48-49
 - cough, hoarseness, and laryngeal complaints, 50-53
 - secondary to acid reflux, 62
 - treatment and, 53
 - dysphagia, nonobstructive, 45, 46
 - extraesophageal, 45-53, 47t
 - heartburn, 43
 - hypersalivation, 44
 - spontaneous remission of, 11
 - typical, 43
 - unsatisfactory pharmacologic control of, surgical alternatives, 169, 170, 170t
- Table salt intake, 114
- Tacrolimus, proton pump inhibitor interaction profile, 153t
- Tagamet. See *Cimetidine*.
- Tea, 115. See also *Theophylline*.
- Temperature sensitivity, 44
- Tetracycline hydrochloride, stricture induced by, 82t
- Theophylline
- lower esophageal sphincter pressure and, 24
 - proton pump inhibitor interaction profile, 153t
- Therapeutic trials (of medications), as part of diagnosis, 45, 59-60
- Therapy for GERD. See *Management of GERD; Nonpharmacologic management of GERD; Pharmacologic management of GERD; Surgical management of GERD*.
- Three-dimensional imaging of LES. See *Lower esophageal sphincter, manometry of*.
- Tissue barrier. See *Esophageal tissue barrier*.
- TLESRs (transient lower esophageal sphincter relaxations), 20, 22-23, 26
- gastric volume and, 29
 - surgical procedures and, 171, 172t
- Tobacco. See *Smoking*.
- Toupet fundoplication, 170-171, 171t, 174, 175

Transient lower esophageal sphincter relaxations. See *TLESRs*.
Treatment of GERD. See *Management of GERD; Nonpharmacologic management of GERD; Pharmacologic management of GERD; Surgical management of GERD*.
Two sphincter hypothesis, of GEJ incompetence, 34

Ulceration

barium esophagoscopy in diagnosis of, 71
endoscopy in diagnosis of, 69

Ulcerative esophagitis, 7

LESP in, 14

United Kingdom General Practice Research Database, 155

Upper esophageal sphincter, 51

Urea breath test, 106t

Urease activity test, 106t

Vagovagal reflexes, 124

Vagus nerve, 23

bronchospasm and, 50
cardiac outflow in acid-sensitive patients, 49
in gastric acid secretion, 123t, 124

Valsalva's maneuver, 34

Vasovagal reflexes, 23, 123t

Vitamin B₁₂ metabolism, 155

Vocal cord granuloma, 47t

Volvulus, paraesophageal hernia and, 34

Vomiting

endoscopy in diagnosis of, 69
regurgitation vs, 43

Warfarin, proton pump inhibitor interaction profile, 153t

Water brash, 27, 28, 44

Water siphon test, 71

Weight loss, 60, 113

adenocarcinoma and, 85
endoscopy in diagnosis of, 69

Wireless pH monitoring device (Bravo pH Probe), 63-65

Young patients

diagnosis and treatment in, 59, 60
Helicobacter pylori treatment recommendation for, 101

Zantac. See *Ranitidine*.

Zegerid. See *Omeprazole/sodium bicarbonate*.